Fox Chase Cancer Center News

PHILADELPHIA (September 11, 2018) – This one-mile walk around Fox Chase Cancer Center’s main campus is a fundraiser for pancreatic cancer research and the postdoctoral research program. Participants will enjoy a variety of vendors, professional pet photos, animal rescue organizations, entertainment, refreshments, contests, and prizes.

PHILADELPHIA (September 10, 2018)— Chemoprevention was effective in reducing the incidence of colorectal cancer in a new study, but the therapies worked differently depending on whether mice presented with or without benign tumors at the time the intervention started. 

PHILADELPHIA (September 6, 2018) – Researchers at Fox Chase Cancer Center have demonstrated for the first time how two diet-dependent signaling pathways fit together to control the health and lifespan of stem cells. Their work shows that manipulating the balance between these pathways can influence how long stem cells live and how long they can reproduce.

PHILADELPHIA (August 29, 2018)—Yanis Boumber, MD, PhD, assistant professor in the Department of Hematology/Oncology, has been awarded a R21 grant from the National Cancer Institute to support research on non-small cell lung cancer.

PHILADELPHIA (August 29, 2018)— Shannon Lynch, PhD, MPH, assistant professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has received a grant from the American Cancer Society to support her efforts to reduce racial disparities in prostate cancer.

PHILADELPHIA (August 29, 2018)— Sergey Grivennikov, PhD, assistant professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has received a R01 grant from the National Cancer Institute to support research on the connection between inflammation and colorectal cancer. The grant will provide approximately $280,000 per year over five years.

Two urologists from California and New York are the newest members of Fox Chase Cancer Center’s Urologic Oncology Fellowship program—they have initiated their 2-year training this summer. The fellowship program annually matches 2 urology residents, providing a unique, higher level and comprehensive experience in the treatment of genitourinary cancers.

PHILADELPHIA (August 27, 2018) – A new study suggests that targeting Group I p21-activated kinases (Paks) with small-molecule inhibitors could be a promising therapeutic approach in colorectal cancer. Researchers led by Jonathan Chernoff, MD, PhD  designed a transgenic mouse model that conditionally expresses an inhibitory peptide to block the catalytic function of Group I Paks, and noted its efficacy in reducing adenomas and impeding progression to carcinomas.